MRUS – merus n.v. - common shares (US:NASDAQ)
Stock Stats
News
Merus N.V. (MRUS): A Bull Case Theory [Yahoo! Finance]
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab [Yahoo! Finance]
Merus (NASDAQ:MRUS) had its "market perform" rating reaffirmed by analysts at BMO Capital Markets.
Merus (NASDAQ:MRUS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
Form 4 Merus N.V. For: Nov 25 Filed by: Lundberg Sven Ante
Form 4 Merus N.V. For: Nov 25 Filed by: Shuman Harry
Form SCHEDULE 13G/A Merus N.V. Filed by: Paradigm Biocapital Advisors LP
Form SCHEDULE 13G/A Merus N.V. Filed by: RTW INVESTMENTS, LP
Form SCHEDULE 13G/A Merus N.V. Filed by: WELLINGTON MANAGEMENT GROUP LLP
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.